Fibrinogen, COPD and mortality in a nationally representative U.S. cohort

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 4, 2012, Pages 359-366

  Mannino, David M ^a,b   Valvi, Deepa ^a   Mullerova, Hana ^c   Tal Singer, Ruth ^d  

^a UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

COPD; Epidemiology; Fibrinogen; Mortality

Indexed keywords

FIBRINOGEN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NUTRITION SURVEYS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84865196783     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.668249     Document Type: Article

References (27)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370:765-773.
2. Minino AM, Xu J, Kochanek KD. Death in the United States, 2008. National Vital Statistics Reports 2010; 59:1-72.
3. Burrows B, Strauss RH, Niden AH. Chronic Obstructive Lung Disease .3. Interrelationships of Pulmonary Function Data. Amer Rev Respir Dis 1965; 91:861-868.
4. Fletcher C, Peto R, Tinker CM, Speizer FE. Th e natural history of chronic bronchitis and emphysema. Oxford University Press, Oxford, UK, 1976.
5. Peto R, Speizer FE, Cochrane AL et al. Th e relevance in adults of air-fl ow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983; 128:491-500.
6. Anthonisen NR. Th e British hypothesis revisited. Euro Respir J 2004; 23:657-658.
7. Vestbo J, Prescott E. Update on the "Dutch hypothesis" for chronic respiratory disease. Thorax 1998; 53 Suppl 2:S15-S19.
8. Sin DD, Man SF, Marciniuk DD, et al. Can inhaled fl uticasone alone or in combination with salmeterol reduce systemic infl ammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial (NCT00120978). BMC Pulm Med 2006; 6:3.
9. Decramer M, Rennard S, Troosters T et al. COPD as
10. Mannino DM, Doherty DE, Buist AS. Global Initiative on Obstructive Lung Disease (GOLD) classifi cation of lung disease and mortality: fi ndings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006; 100:115-122.
11. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax 2008; 63:599-605.
12. Redman CM, Xia H. Fibrinogen biosynthesis. Assembly, intracellular degradation, and association with lipid synthesis and secretion. Ann NY Acad Sci 2001; 936:480-495.
13. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fi brinogen and serum IL-6 levels. Thromb Haemost 2000; 84:210-215.
14. Engstrom G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: relationship with infl ammation-sensitive plasma proteins. Circulation 2002; 106:2555-2560.
15. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fi brinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1008-1011.
16. Ford ES, Giles WH. Serum C-reactive protein and fi brinogen concentrations and self- reported angina pectoris and myocardial infarction: fi ndings from National Health and Nutrition Examination Survey III. J Clin Epidemiol 2000; 53:95-102.
17. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of infl ammation: data from the Th ird National Health and Nutrition Examination. Am J Med 2003; 114:758-762.
18. Gunter EW, Lewis B, Koncikowski S. Laboratory Procedures Used for the Th ird National Health and Nutrition Examination Survey (NHANES III), 1988-1994. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, 1996.
19. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179-187.
20. Rodriguez-Roisin R, Rabe KF, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2008 Update). www. goldcopd.org. 2009. 4-26-2011.
21. Lowe GD, Rumley A, Mackie IJ. Plasma fi brinogen. Ann Clin Biochem 2004; 41:430-440.
22. De Maat MP, Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 2005; 12:377-383.
23. Engstrom G, Segelstorm N, Ekberg-Aronsson M, et al. Plasma markers of infl ammation and incidence of hospitalisations for COPD: results from a population-based cohort study. Thorax 2009; 64:211-215.
24. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? Th e potential role of systemic infl ammation in chronic obstructive pulmonary disease. Circulation 2003; 107:1514-1519.
25. Gunen H, Gulbas G, In E, Yetkin O, Hacievliyagil SS. Venous thromboemboli and exacerbations of COPD. Eur Respir J 2010; 35:1243-1248.
26. Hyatt RE, Cowl CT, Bjoraker JA, Scanlon PD. Conditions associated with an abnormal nonspecifi c pattern of pulmonary function tests. Chest 2009; 135:419-424.
27. Lomas DA, Miller BE, Willitis L, Keene O, Barnacle H, Barnes NC, et al. Inhibition of p38 MAP kinase reduces plasma fi brinogen in COPD. J Clin Pharmacol. In press.